Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 7
1991 10
1992 14
1993 11
1994 7
1995 3
1996 8
1997 8
1998 19
1999 14
2000 16
2001 20
2002 13
2003 29
2004 20
2005 28
2006 33
2007 53
2008 80
2009 84
2010 82
2011 100
2012 103
2013 130
2014 135
2015 154
2016 154
2017 149
2018 149
2019 68
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

1,508 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).
McDonald LC, et al. Clin Infect Dis 2018. PMID 29462280 Free PMC article.
A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. ...Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. ...
A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHE …
Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms.
Banawas SS. Biomed Res Int 2018 - Review. PMID 29682562 Free PMC article.
Clostridium difficile (C. difficile) is the most prevalent causative pathogen of healthcare-associated diarrhea. Notably, over the past 10 years, the number of Clostridium difficile outbreaks has increased with the rate of morbidity and mortality. ...Most C. difficile isolates are still susceptible to metronidazole and vancomycin. Incidences of C. difficile resistance to other antimicrobial drugs have also been reported. ...
Clostridium difficile (C. difficile) is the most prevalent causative pathogen of healthcare-associated diarrhea. Notabl
Update of treatment algorithms for Clostridium difficile infection.
Ooijevaar RE, et al. Clin Microbiol Infect 2018 - Review. PMID 29309934 Free article.
BACKGROUND: Clostridium difficile is the leading cause of antibiotic-associated diarrhoea, both in healthcare facilities and in the community. ...Completed phase 2 studies were found for cadazolid, LFF571, ridinilazole and nontoxigenic C. difficile strains. Four phase 3 active comparator studies comparing vancomycin with bezlotoxumab, surotomycin (n = 2) and rifaximin have been published. ...
BACKGROUND: Clostridium difficile is the leading cause of antibiotic-associated diarrhoea, both in healthcare facilities and i …
Antibiotic Resistances of Clostridium difficile.
Spigaglia P, et al. Adv Exp Med Biol 2018 - Review. PMID 29383668
The rapid evolution of antibiotic resistance in Clostridium difficile and the consequent effects on prevention and treatment of C. difficile infections (CDIs) are matter of concern for public health. ...Different transfer mechanisms facilitate the spread of mobile elements among C. difficile strains and between C. difficile and other species. ...
The rapid evolution of antibiotic resistance in Clostridium difficile and the consequent effects on prevention and trea …
Advances in the diagnosis and treatment of Clostridium difficile infections.
Peng Z, et al. Emerg Microbes Infect 2018 - Review. PMID 29434201 Free PMC article.
Clostridium difficile is a leading cause of antibiotic-associated diarrhea worldwide. The diagnosis of C. difficile infection (CDI) requires both clinical manifestations and a positive laboratory test for C. difficile and/or its toxins. ...A number of emerging agents such as cadazolid, surotomycin, ridinilazole, and bezlotoxumab have demonstrated activity against C. difficile; some of these have been approved for limited clinical use and some are in clinical trials. ...
Clostridium difficile is a leading cause of antibiotic-associated diarrhea worldwide. The diagnosis of C. difficile inf
Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.
Peng Z, et al. J Clin Microbiol 2017 - Review. PMID 28404671 Free PMC article.
Oral antibiotics such as metronidazole, vancomycin and fidaxomicin are therapies of choice for Clostridium difficile infection. ...This update summarizes new information published since 2010 on phenotypic and genotypic resistance mechanisms in C. difficile and addresses susceptibility test methods and other strategies to counter antibiotic resistance of C. difficile....
Oral antibiotics such as metronidazole, vancomycin and fidaxomicin are therapies of choice for Clostridium difficile infection …
Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis.
Beinortas T, et al. Lancet Infect Dis 2018. PMID 30025913 Free article.
BACKGROUND: Several new treatments for Clostridium difficile infections have been investigated. We aimed to compare and rank treatments for non-multiply recurrent infections with C difficile in adults. METHODS: We did a random effects network meta-analysis within a frequentist setting to obtain direct and indirect comparisons of trials. ...
BACKGROUND: Several new treatments for Clostridium difficile infections have been investigated. We aimed to compare and rank t …
Fidaxomicin--the new drug for Clostridium difficile infection.
Vaishnavi C. Indian J Med Res 2015 - Review. PMID 26112840 Free PMC article.
Clostridium difficile is one of the many aetiological agents of antibiotic associated diarrhoea and is implicated in 15-25 per cent of the cases. ...Due to increase in the incidence of C. difficile infection (CDI), emergence of hypervirulent strains, and increased frequency of recurrence, the clinical management of the disease has become important. ...
Clostridium difficile is one of the many aetiological agents of antibiotic associated diarrhoea and is implicated in 15-25 per
Clostridium difficile drug pipeline: challenges in discovery and development of new agents.
Jarrad AM, et al. J Med Chem 2015 - Review. PMID 25760275 Free PMC article.
In the past decade Clostridium difficile has become a bacterial pathogen of global significance. Epidemic strains have spread throughout hospitals, while community acquired infections and other sources ensure a constant inoculation of spores into hospitals. ...However, bringing a new treatment for C. difficile infection to market involves particular challenges. This review covers the current drug discovery pipeline, including both small molecule and biologic therapies, and highlights the challenges associated with in vitro and in vivo models of C. difficile infection for drug screening and lead optimization....
In the past decade Clostridium difficile has become a bacterial pathogen of global significance. Epidemic strains have spread …
Clostridium difficile Biofilm.
Vuotto C, et al. Adv Exp Med Biol 2018 - Review. PMID 29383666
Clostridium difficile infection (CDI) is an important healthcare-associated disease worldwide, mainly occurring after antimicrobial therapy. ...However, although the involvement of the C. difficile biofilm in the pathogenesis and recurrence of CDI is attracting more and more interest, the mechanisms underlying biofilm formation of C. difficile as well as the role of biofilm in CDI have not been extensively described.Findings on C. difficile biofilm, possible implications in CDI pathogenesis and treatment, efficacy of currently available antibiotics in treating biofilm-forming C. difficile strains, and some antimicrobial alternatives under investigation will be discussed here....
Clostridium difficile infection (CDI) is an important healthcare-associated disease worldwide, mainly occurring after antimicr
1,508 results
Jump to page
Feedback